Sorafenib (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sorafenib" in Italian language version.

refsWebsite

Global rank Italian rank

9doi.org

2^nd place

7^th place

8nih.gov

4^th place

9^th place

6oadoi.org

799^th place

22^nd place

6web.archive.org

1^st place

3fda.gov

447^th place

644^th place

1europa.eu

68^th place

57^th place

1bbc.co.uk

8^th place

23^rd place

1wipo.int

1,462^nd place

4,222^nd place

1nejm.org

2,374^th place

1,283^rd place

1medscape.com

719^th place

799^th place

1archive.org

6^th place

8^th place

archive.org

Dasanu CA, Alexandrescu DT, Dutcher J, Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma, in South. Med. J., vol. 100, n. 3, marzo 2007, pp. 328–30, DOI:10.1097/SMJ.0b013e31802f01a9, PMID 17396743.

bbc.co.uk

news.bbc.co.uk

Liver drug 'too expensive', su news.bbc.co.uk, BBC News, 19 novembre 2009. URL consultato il 10 novembre 2012.

doi.org

dx.doi.org

Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M, CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations, in Oncogene, vol. 28, n. 1, gennaio 2009, pp. 85–94, DOI:10.1038/onc.2008.362, PMC 2898184, PMID 18794803.
Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling, in Mol. Cancer Ther., vol. 7, n. 10, ottobre 2008, pp. 3129–40, DOI:10.1158/1535-7163.MCT-08-0013, PMID 18852116.
Keating GM, Santoro A, Sorafenib: a review of its use in advanced hepatocellular carcinoma, in Drugs, vol. 69, n. 2, 2009, pp. 223–40, DOI:10.2165/00003495-200969020-00006, PMID 19228077.
Seven days: 9–15 March 2012, in Nature, vol. 483, n. 7389, 2012, pp. 250–1, DOI:10.1038/483250a.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, Sorafenib in advanced clear-cell renal-cell carcinoma, in N. Engl. J. Med., vol. 356, n. 2, gennaio 2007, pp. 125–34, DOI:10.1056/NEJMoa060655, PMID 17215530.
Walid MS, Johnston KW, Successful treatment of a brain-metastasized renal cell carcinoma, in Ger Med Sci, vol. 7, 2009, pp. Doc28, DOI:10.3205/000087, PMC 2775194, PMID 19911072.
Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF, Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma, in J. Clin. Oncol., vol. 29, n. 30, ottobre 2011, pp. 3960–7, DOI:10.1200/JCO.2011.37.1021, PMID 21911714.
Dasanu CA, Alexandrescu DT, Dutcher J, Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma, in South. Med. J., vol. 100, n. 3, marzo 2007, pp. 328–30, DOI:10.1097/SMJ.0b013e31802f01a9, PMID 17396743.
Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA, Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib, in J. Clin. Oncol., vol. 26, n. 24, agosto 2008, pp. 4047–8, DOI:10.1200/JCO.2008.18.3525, PMID 18711201.

europa.eu

ec.europa.eu

European Commission – Enterprise and industry. Nexavar Archiviato il 1º febbraio 2008 in Internet Archive.. Retrieved April 24, 2007.

fda.gov

accessdata.fda.gov

fda.gov

FDA Approves Nexavar for Patients with Inoperable Liver Cancer, su fda.gov, FDA, 19 novembre 2007. URL consultato il 10 novembre 2012.

medscape.com

"Addition of Sorafenib May Be Detrimental in Some Lung Cancer Patients"

nejm.org

http://www.nejm.org/doi/full/10.1056/NEJMoa0708857 Llovet, et al., Sorafenib in Advanced Hepatocellular Carcinoma, in NEJM, vol. 359, 2008, pp. 378–90.

nih.gov

ncbi.nlm.nih.gov

Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M, CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations, in Oncogene, vol. 28, n. 1, gennaio 2009, pp. 85–94, DOI:10.1038/onc.2008.362, PMC 2898184, PMID 18794803.
Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling, in Mol. Cancer Ther., vol. 7, n. 10, ottobre 2008, pp. 3129–40, DOI:10.1158/1535-7163.MCT-08-0013, PMID 18852116.
Keating GM, Santoro A, Sorafenib: a review of its use in advanced hepatocellular carcinoma, in Drugs, vol. 69, n. 2, 2009, pp. 223–40, DOI:10.2165/00003495-200969020-00006, PMID 19228077.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, Sorafenib in advanced clear-cell renal-cell carcinoma, in N. Engl. J. Med., vol. 356, n. 2, gennaio 2007, pp. 125–34, DOI:10.1056/NEJMoa060655, PMID 17215530.
Walid MS, Johnston KW, Successful treatment of a brain-metastasized renal cell carcinoma, in Ger Med Sci, vol. 7, 2009, pp. Doc28, DOI:10.3205/000087, PMC 2775194, PMID 19911072.
Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF, Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma, in J. Clin. Oncol., vol. 29, n. 30, ottobre 2011, pp. 3960–7, DOI:10.1200/JCO.2011.37.1021, PMID 21911714.
Dasanu CA, Alexandrescu DT, Dutcher J, Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma, in South. Med. J., vol. 100, n. 3, marzo 2007, pp. 328–30, DOI:10.1097/SMJ.0b013e31802f01a9, PMID 17396743.
Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA, Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib, in J. Clin. Oncol., vol. 26, n. 24, agosto 2008, pp. 4047–8, DOI:10.1200/JCO.2008.18.3525, PMID 18711201.

oadoi.org

Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling, in Mol. Cancer Ther., vol. 7, n. 10, ottobre 2008, pp. 3129–40, DOI:10.1158/1535-7163.MCT-08-0013, PMID 18852116.
Keating GM, Santoro A, Sorafenib: a review of its use in advanced hepatocellular carcinoma, in Drugs, vol. 69, n. 2, 2009, pp. 223–40, DOI:10.2165/00003495-200969020-00006, PMID 19228077.
Seven days: 9–15 March 2012, in Nature, vol. 483, n. 7389, 2012, pp. 250–1, DOI:10.1038/483250a.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, Sorafenib in advanced clear-cell renal-cell carcinoma, in N. Engl. J. Med., vol. 356, n. 2, gennaio 2007, pp. 125–34, DOI:10.1056/NEJMoa060655, PMID 17215530.
Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF, Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma, in J. Clin. Oncol., vol. 29, n. 30, ottobre 2011, pp. 3960–7, DOI:10.1200/JCO.2011.37.1021, PMID 21911714.
Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA, Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib, in J. Clin. Oncol., vol. 26, n. 24, agosto 2008, pp. 4047–8, DOI:10.1200/JCO.2008.18.3525, PMID 18711201.

web.archive.org

Sorafenib Sunitinib differences, su healthvalue.net. URL consultato il 15 agosto 2007 (archiviato dall'url originale il 18 luglio 2007).Template:MEDRS
European Commission – Enterprise and industry. Nexavar Archiviato il 1º febbraio 2008 in Internet Archive.. Retrieved April 24, 2007.
Nexavar® (Sorafenib) Approved for Hepatocellular Carcinoma in Europe, su pslgroup.com, Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, 30 ottobre 2007. URL consultato il 10 novembre 2012 (archiviato dall'url originale il 6 febbraio 2012).
UPDATE 1-Bayer loses landmark Indian drug case over Nexavar | Reuters, su reuters.com. URL consultato il 4 maggio 2019 (archiviato dall'url originale il 21 ottobre 2012).
Copia archiviata (PDF), su ipindia.nic.in. URL consultato il 2 aprile 2012 (archiviato dall'url originale il 21 marzo 2012).
"Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer", su lifescience-online.com. URL consultato il 18 settembre 2013 (archiviato dall'url originale il 3 dicembre 2013).

wipo.int

India Patents (Amendment) Act, 2005, su wipo.int, WIPO. URL consultato il 16 gennaio 2013.